Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Money and Politics Put World’s Biggest Climate Deal at Risk
A new 'Antarctica' accent has been discovered by scientists
China to Curb Graphite Exports. What It Means for Tesla and Other EV Stocks.
Australia issues $386,000 fine against X over failure to cooperate with child sex abuse probe
Bentley Systems’ iTwin Ventures Acquires Blyncsy, Breakthrough Innovator in AI Services for Transportation Operations and Maintenance
Kranti Ponnam, Esteemed Business Leader, Joins Forbes Business Council
Instagram Threads: What happens to account if connected Instagram profile is set to private?
Sensata Technologies Launches New Compact Battery Management System with Advanced Software Features for Industrial Applications and Low Voltage Electric Vehicles